Get the Stockscreener App
3.28
3.80%
0.12
After Hours:
3.28
Genenta Science Spa Adr stock is traded at $3.28, with a volume of 13,149.
It is up +3.80% in the last 24 hours and down -4.65% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$3.16
Open:
$3.01
24h Volume:
13,149
Relative Volume:
1.47
Market Cap:
$59.99M
Revenue:
-
Net Income/Loss:
$-12.63M
P/E Ratio:
-4.7249
EPS:
-0.6942
Net Cash Flow:
$-12.18M
1W Performance:
+0.45%
1M Performance:
-4.65%
6M Performance:
-7.92%
1Y Performance:
-34.40%
1-Day Range:
$3.00
$3.39
1-Week Range:
$3.00
$3.39
52-Week Range:
$2.56
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.28 | 57.80M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Can Genenta Science S.p.A. (Common Stock) (K5F) stock hold up in economic slowdownGap Down & Community Driven Trade Alerts - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Stock Price Down 1.9%Here's What Happened - MarketBeat
Analyzing Genenta Science S.p.A. Depositary Receipt with multi timeframe chartsWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Genenta Science (NASDAQ:GNTA) Trading 7.4% HigherHere's Why - MarketBeat
Real time alert setup for Trinity Capital Inc. performanceJuly 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Using data filters to optimize entry into Genenta Science S.p.A. Depositary ReceiptJuly 2025 News Drivers & High Accuracy Investment Signals - Newser
Assembly Biosciences Inc. stock trend outlook and recovery pathGDP Growth & Safe Capital Growth Tips - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Genenta Science (NASDAQ:GNTA) Trading 7.4% Higher – Time to Buy? - Defense World
Will Genenta Science S.p.A. Depositary Receipt stock go up soonJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
How moving averages guide Genenta Science S.p.A. Depositary Receipt tradingTrade Signal Summary & Safe Capital Investment Plans - Newser
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar - GlobeNewswire Inc.
Genenta secures $21.9 million for cancer drug trial - Investing.com
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Trading Halts Explained - MarketBeat
Stock Market Alerts - MarketBeat
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):